Domantis Limited

8 patents currently held · Updated Nov 14, 2026

7 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Sep 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Jul 5 to 28, 2027 · next Jul 5

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Patent	Title	Status	Expires	Confidence
US 8,236,931	Prevention of aggregation of immunoglobulin light or heavy chains In force Term ends Sep 23, 2028 · From the USPTO record	In force	Term ends Sep 23, 2028	From the USPTO record
US 8,357,780	Polypeptides, antibody variable domains and antagonists methods for In force Term ends Jan 3, 2029 · From the USPTO record	In force	Term ends Jan 3, 2029	From the USPTO record
US 8,921,528	Bispecific fusion antibodies with enhanced serum half-life In force Term ends Aug 23, 2029 · From the USPTO record	In force	Term ends Aug 23, 2029	From the USPTO record
US 10,919,965	Compositions Monovalent for CD28 Binding and Methods of Use In force Term ends Apr 20, 2030 · High confidence	In force	Term ends Apr 20, 2030	High confidence
US 8,981,072	Nucleic Acids Encoding Antibody Polypeptides That Antagonize CD40L In force Term ends Oct 12, 2032 · High confidence	In force	Term ends Oct 12, 2032	High confidence
US 9,228,018	Antibody Polypeptides That Antagonize CD40L In force Term ends Oct 12, 2032 · High confidence	In force	Term ends Oct 12, 2032	High confidence
US 10,544,228	Nucleic Acids Encoding Antibody Polypeptides That Antagonize CD40 In force Term ends Feb 2, 2033 · Medium confidence	In force	Term ends Feb 2, 2033	Medium confidence
US 9,475,879	Antibody polypeptides that antagonize CD40 In force Term ends Mar 12, 2033 · From the USPTO record	In force	Term ends Mar 12, 2033	From the USPTO record

Also on record, not counted in the 8: 7 patents in force now held by others · 21 lapsed for an unpaid fee · 6 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 abandoned · 45 no status recorded

List them